Weiter zum Inhalt
Toggle navigation
English
English
Favoritenliste (
0
)
(Voll)
Kontakt
Mein Konto
Abmeldung
Mein Konto
Suche
Filter bei nächster Suche beibehalten
publishDate:"[2020 TO 2029]"
topic_facet:"Recruitment Status: Authorised-recruitment may be ongoing or finished"
Erweiterte Suche
Suchverlauf
Struktursuche
Narrative Service
Drug Overviews
Info Guide
/vufind/Search/Results?filter%5B%5D=publishDate%3A%22%5B2020+TO+2029%5D%22&filter%5B%5D=topic_facet%3A%22Recruitment+Status%3A+Authorised-recruitment+may+be+ongoing+or+finished%22&lookfor=%22Female%22&type=Subject
/vufind/Search/Results?filter%5B%5D=publishDate%3A%22%5B2020+TO+2029%5D%22&filter%5B%5D=topic_facet%3A%22Recruitment+Status%3A+Authorised-recruitment+may+be+ongoing+or+finished%22&lookfor=%22Female%22&type=Subject
Search /vufind/Search2/Results?filter%5B%5D=publishDate%3A%22%5B2020+TO+2029%5D%22&filter%5B%5D=topic_facet%3A%22Recruitment+Status%3A+Authorised-recruitment+may+be+ongoing+or+finished%22&lookfor=%22Female%22&type=Subject
PubPharm (600)
1
A study to determine whether the addition of TSR-042, followed by the use of niraparib with TSR-042, delays recurrence of ovarian, primary peritoneal or fallopian tube cancer : A Randomized, Double-Blind, Phase 3 Comparison of Platinum-Based Therapy with TSR-042 and Niraparib Versus Standard of Care Platinum-Based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer - The FIRST (First-line ovarian cancer treatment with Niraparib plus TSR 042) Study
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
2
A Phase 3 Trial Comparing Selpercatinib to Cabozantinib or Vandetanib in Patients with RET-Mutant Medullary Thyroid Cancer : A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing Selpercatinib to Physicians Choice of Cabozantinib or Vandetanib in Patients with Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
3
A Clinical Trial for Newly Diagnosed High Risk Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer : A Randomized, Multicenter, Double-blind, Placebo-controlled Phase 3 Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Patients With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer(CheckMate 7FL: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 7FL) - Nivo/Placebo with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in ER+/HER2-Breast Cancer
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
4
Benefit of treatment with a GnRH agonist (neurohormone) prior to frozen embryo transfer in patients with endometriosis (endometrial disease) and / or adenomyosis (another form of endometriosis) : Benefit of the GnRH agonist before frozen embryo transfer in patients with endometriosis and / or adenomyosis: randomized prospective study - DECATEC
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
5
A Trial Comparing LOXO-292 to Chemotherapy in Patients with Non-Small Cell Lung Cancer : A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing LOXO-292 to Platinum-Pemetrexed Chemotherapy Plus Investigator’s Choice of Pembrolizumab in Patients with Advanced, Treatment-Naïve RET Fusion-Positive Non-Small Cell Lung Cancer - LIBRETTO-431
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
6
Trial for the optimisation of risk assessment and therapy success predicition in patients with early breast cancer by the use of biomarkers in advance to therapy decission-making to personalize therapies. : Adjuvant Dynamic marker-Adjusted Personalized Therapy trial optimizing risk assessment and therapy response prediction in early breast cancer - ADAPT
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
7
A study investigating whether progesterone supplementation in otherwise unmedicated, natural menstrual cycles can improve live birth rates : A Randomised Controlled trial investigating the effects of Progesterone for luteal phase support in Natural Cycles for unexplained infertility - Progesterone in Natural Cycles (PiNC)
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
8
A study to determine whether the addition of TSR-042, followed by the use of niraparib with TSR-042, delays recurrence of ovarian, primary peritoneal or fallopian tube cancer : A Randomized, Double-Blind, Phase 3 Comparison of Platinum-Based Therapy with TSR-042 and Niraparib Versus Standard of Care Platinum-Based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer - The FIRST (First-line ovarian cancer treatment with Niraparib plus TSR 042) Study
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
9
A Phase 3 Trial Comparing Selpercatinib to Cabozantinib or Vandetanib in Patients with RET-Mutant Medullary Thyroid Cancer : A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing Selpercatinib to Physicians Choice of Cabozantinib or Vandetanib in Patients with Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
10
A Clinical Trial for Newly Diagnosed High Risk Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer : A Randomized, Multicenter, Double-blind, Placebo-controlled Phase 3 Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Patients With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer(CheckMate 7FL: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 7FL) - Nivo/Placebo with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in ER+/HER2-Breast Cancer
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
1
2
3
4
5
6
7
8
9
10
11
Nächster »
[60]
Filter & Sortierung
Treffer pro Seite
10
20
50
Sortieren
Relevanz
Neueste zuerst
Älteste zuerst
Verfasser
Zeitschriftentitel
Bibliothek
Standort (Printmedien)
Verwandte Substanzen
Verwandte Substanzen werden ermittelt...
Verwandte Erkrankungen/Symptome
Verwandte Erkrankungen/Symptome werden ermittelt...
Verwandte Gene
Verwandte Gene werden ermittelt...
Systematic Reviews
Clinical Studies
Patente
Covid-19/SARS-CoV-2
Exclude Systematic Reviews
Exclude Clinical Studies
Exclude Patents
Ihre gewählten Filter
Filter bei nächster Suche beibehalten
Filter aufheben
Alle gewählten Filter entfernen
Filter aufheben
Erscheinungsjahr: 2020-2029
Filter aufheben
Thema: Recruitment Status: Authorised-recruitment may be ongoing or finished
Medienart
600
Aufsätze
600
E-Artikel
600
E-Ressourcen
Zeitschriftentitel
600
WHO International Clinical Trials Registry Plat...
Thema
600
610
Recruitment Status: Authorised-recruitment may ...
600
Study Type: Interventional
384
Phase: Phase 3
126
Phase: Phase 2
76
Phase: Phase 4
28
Medical Condition: Vasomotor symptoms associate...
24
Medical Condition: Endometriosis MedDRA version...
20
Medical Condition: Patients With High-risk, Est...
20
Medical Condition: Recurrent or primary advance...
18
Medical Condition: Male or female patients with...
16
Medical Condition: Advanced triple negative bre...
16
Medical Condition: Male or female patients with...
16
Medical Condition: Stage 3 or 4 High Grade Non-...
14
Medical Condition: Male and female participants...
14
Phase: Phase 1
12
Medical Condition: Endometriosis-associated pai...
12
Medical Condition: Locally advanced (inoperable...
12
Medical Condition: Male and female participants...
10
Medical Condition: Adjuvant Selpercatinib follo...
Alle anzeigen ...
weniger ...
Erscheinungszeitraum
2020-
40
2023
162
2022
270
2021
128
2020
Alle anzeigen ...
weniger ...
Erscheinungsjahr(e)
Von:
Bis:
Sprache
592
Englisch
6
Unbestimmt
2
Deutsch
Haven't found what you're looking for?
Wird geladen...